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We tested a low-cost, multifaceted intervention program comprising formulary restriction measures, continued
comprehensive education, and guidelines to improve in-hospital use of antibiotics and related costs. In a
short-term analysis, total antibiotic consumption per patient admitted, which was expressed as defined daily
doses (DDD), decreased by 36% ( ), and intravenous DDDs decreased by 46% ( ). Overall ex-P ! .001 P ! .01
penditures for antibiotic treatment decreased by 53% (US$100 per patient admitted). The 2 main cost-lowering
factors were a reduction in prescription of antibiotics (35% fewer treatments; ) and more diligentP ! .0001
use of 5 broad-spectrum antibiotics (23% vs. 10% of treatments; ). Quality of care was not compro-Pp .001
mised. A pharmacy-based, prospective, long-term surveillance of DDDs and costs over 4 years showed an
ongoing effect. This comprehensive intervention program, which aimed to reduce antibiotic consumption and
costs, was highly successful and had long-lasting effects.
Antibiotics may account for up to 30% of a hospital’s
drug budget [1–3]. For many years, inappropriate use
of antibiotics has been recognized as a major problem
and a reason for high costs, as well as the selection and
spread of drug-resistant microorganisms [4–7]. Various
strategies have been used to implement guidelines and
antimicrobial-control programs to reduce costs and
limit the emergence and spread of antimicrobial-resis-
tant organisms [8, 9]. Strategies include education, for-
mulary restriction (i.e., mandatory approval of certain
restricted antibiotics by clinical pharmacists or infec-
tious diseases specialists), pharmacy justification, for-
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mulary substitution, early switch from intravenous to
oral delivery, computer surveillance, and multidiscipli-
nary approaches [9]. Cost-saving effects were demon-
strated in several studies [3, 10–22], but, with a one
exception [15], the duration of follow-up was mostly
short (!2 years). Most studies dealt with interdiscipli-
nary interventions performed at large medical centers
[3, 10, 12, 13, 17–22], where hospital staff made de-
cisions about antibiotic use in direct or indirect inter-
action with clinical pharmacists and infectious diseases
specialists or with the help of computer decision-
support systems [14, 15]. However, smaller hospitals
with less sophisticated computer systems may face dif-
ficulties in implementing programs like these [15].
We developed a multifaceted intervention program
in response to a steady increase in the use and costs of
antibiotics in our department since 1992. Our program
combines several well-known methods, such as broad
education, guidelines, formulary restriction, special ap-
proval for certain restricted drugs, and early switches
from intravenous to oral therapy. The program
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was continuously enforced over a period of 4 years and was
designed to particularly address the needs of a medical de-
partment in a small-sized teaching hospital. The objective of
the present study was 2-fold: to evaluate the short-term effect
of the program on costs and clinical outcomes in individual
patients, and to monitor the long-term effect on costs on the
basis of data provided by the hospital pharmacy in the years
after the implementation of the program.
PATIENTS AND METHODS
Setting. The Department of Internal Medicine of the Kan-
tonsspital Schaffhausen, Switzerland, is a tertiary care center
with 80 beds and the only hospital in a region of ∼80,000
inhabitants. Thus, patients are nonselected and the disease spec-
trum is broad. The staff of the department consists of 13 res-
idents in general internal medicine, who usually rotate every 2
years, and 5 staff physicians and attendants with a specialty in
general internal medicine. The department admits ∼2200 pa-
tients per year.
Study design. This is a quasi-experimental study, with
chart review of 500 consecutive patients admitted in the period
before and after implementation of the program. Use of an-
tibiotics and their costs, as documented in pharmacy records,
were analyzed in the 4 years after implementation of the
program.
Patients. For the short-term analysis, we analyzed 500
consecutive patients admitted after full implementation of the
program by 1 January 1998 and compared these with 500 con-
secutive patients admitted in 1997 (i.e., the last group of pa-
tients who were admitted before the program was initiated).
All patients aged 18 years who were admitted to the general
wards or the intensive care unit (ICU) and who stayed in hos-
pital for 124 h were included. There were no exclusions.
Every patient admitted to the Department of Internal Med-
icine was included in the prospective, pharmacy-based 4-year
follow-up study of antibiotic expenditures. Costs for patients
admitted to the ICU were analyzed separately because the hos-
pital pharmacy could not distinguish medical from nonmedical
patients, with the former making up two-thirds of the ICU
population. Therefore, costs for ICU patients are based on those
for medical and surgical patients, but the latter are not part of
the intervention program.
Intervention. The antimicrobial formulary was reeval-
uated, judged to be reasonable, and left unchanged. Mandatory
approval by a staff physician for restricted drugs (ceftriaxone
[with the exception of its use for the treatment of meningitis],
ceftazidime, piperacillin-tazobactam, imipenem-cilastatin, and
vancomycin) had been introduced several years earlier and was
reinforced. A comprehensive educational program and written
guidelines were established. We introduced the intervention
program in a stepwise manner starting in May 1997, with full
implementation by the end of 1997. The head of the department
(S.R.) was responsible for implementation, maintenance, con-
tinuous surveillance, and outcome evaluation.
The education program comprised the following:
• Provision of the latest antimicrobial cost data and presen-
tation of the intended intervention program to the medical
staff.
• Lecture on appropriate use of antimicrobial drugs, with spe-
cial emphasis on the avoidance of unnecessary treatments.
• Instruction on the indications for a priori oral application
of an antibiotic or for a switch from intravenous to oral
delivery as early as possible.
• Lectures on clinical presentation, diagnosis, and treatment
of the most important and most frequent infectious diseases.
• Weekly rounds with the medical staff on every ward to
evaluate antimicrobial treatments on the basis of the guide-
lines, as outlined below.
• Regular feedback every 6 months to the medical staff re-
garding antimicrobial expenditures.
• Regular yearly provision of hospital antimicrobial suscep-
tibility patterns.
In addition, written guidelines were established on (1) the
appropriateness of empirical antimicrobial treatment, including
a checklist to be considered before start of therapy; (2) the
appropriate choice of antibiotics during the empirical phase,
and once culture results and susceptibility patterns of the caus-
ative organism were known; and (3) the route of delivery, dos-
ing, and duration of treatment for the most important infec-
tions. Recommendations were based on the severity of disease,
the most likely causative organisms, and their resistance pattern
at our hospital. The guidelines are accessible for each physician
in a personal booklet and on the hospital’s internal Web site.
They are modified by the responsible physician whenever nec-
essary, and changes are immediately communicated to the med-
ical staff. The head of the department advised the medical team
to follow the guidelines, but patient care and choice of anti-
biotics were left to the discretion of the treating physicians.
Quality assessment. We included the following parameters
to measure the overall quality of care provided before and after
implementation of the program: overall in-hospital survival,
reasons for death, in-hospital clinical improvement or cure of
patients treated with antibiotics, duration of hospital stay for
all patients and for those treated with antimicrobial drugs, the
number of patients who experienced a relapse during the hos-
pital stay, and the rehospitalization rate within 30 days after
discharge.
Data collection. The following data were abstracted by
one of the authors (B.K.) from the medical charts of the 1000
patients: age, sex, principal diagnosis, infectious disease diag-
nosis, length of hospital stay, and cause of death. Additional
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Table 1. Characteristics of patients and conditions leading to antimicrobial treatment
before and after establishment of the intervention program.
Characteristic
Before
intervention
(n p 500)
After
intervention
(n p 500) P
Age, mean years  SD 67  17 66  18 …
Sex …
Male 254 270
Female 246 230
Principal diagnosisa
Cardiovascular disease 113 (23) 136 (27) …
Infectious disease 85 (17) 57 (11) …
Cerebrovascular or other neurological disease 66 (13) 61 (12) …
Cancer 54 (11) 59 (12) …
Gastrointestinal disease 50 (10) 57 (11) …
Lung disease 50 (10) 35 (7) …
Neuropsychiatric disease 27 (5) 34 (7) …
Other 55 (11) 51 (10) …
Conditions leading to prescription of antibiotics 232 (46) 148 (30) !.0001
Respiratory tract infection 109 (22) 72 (14) .002
Urinary tract infection 46 (9) 32 (6) .01
Gastrointestinal and abdominal infection 29 (6) 6 (1) .0001
Fever and suspected bacterial infection 20 (4) 16 (3) .50
Cellulitis 13 (3) 10 (2) .53
Otherb 15 (3) 12 (2) .56
C-reactive protein levelc
Highest, mean mg/L (range) 122 (!10–582) 159 (!10–588) …
1250 mg/L 27 (11.6) 32 (21.6) .01
1300 mg/L 12 (5.2) 21 (14.2) .002
Length of hospital stay, days
All patients
Median (range) 11 (1–110) 9 (1–87) …
Mean  SD 13.8  12.4 12.4  12.2 …
Treated patients
Median (range) 13 (1–110) 12 (1–87) …
Mean  SD 16.8  15.1 17.5  16.4 …
NOTE. Data are no. (%) of patients, unless otherwise indicated.
a As noted in the charts at the time of discharge from the hospital.
b Sepsis, meningitis, endocarditis, or prophylaxis of endocarditis.
c In patients treated with antibiotics; normal level, !5 mg/L.
data were collected for patients who received 1 dose of an
antibiotic: name, dosage, duration, and route of administration,
including timing for intravenous to oral switch for each anti-
biotic delivered, diagnosis leading to antibiotic treatment, suc-
cess of antibiotic therapy (defined as clinical improvement,
allowing withdrawal from therapy or discharge from the hos-
pital), continuation of antibiotic therapy after discharge, and
reasons for rehospitalization in the month after discharge. Sus-
ceptibility patterns of bacterial organisms were regularly fol-
lowed by our Division of Infection Control.
Statistical analysis. The consumption of antibiotics is pre-
sented as number of defined daily doses (DDDs) [23]. Drug
costs are based on public prices in Switzerland and were con-
verted to US dollars (1 $0.67). Drug prices remainedCHFp US
constant for the drugs in question during the entire study pe-
riod and were thus not updated according to the Consumer
Price Index, which remained flat during 1996–2001 (overall
increase, 4.4%). Cost calculations for nurses’ workloads for
intravenous treatment are based on a standardized system of
workload measure (LEP; LEP AG) and on the usual wages in
Switzerland. We calculated the following summary measures:
(1) sum of intravenous and oral DDDs, and (2) sum of anti-
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Table 2. Defined daily doses (DDDs) of antibiotics delivered.
Variable
No. of DDDs
Difference,
% P
Before
intervention
After
intervention
All patients
Total 2126 1359 36 .001
Intravenous therapy 797 427 46 .01
Oral therapy 1329 932 30 .01
Per patient admitteda
Mean total 4.3 2.7 36 .001
Intravenous therapy 1.6 0.8 46 .01
Oral therapy 2.7 1.9 30 .01
Per patient treatedb
Mean total 9.2 9.2 0 .99
Intravenous therapy 3.4 2.9 15 .45
Oral therapy 5.8 6.3 +9 .35
Per 1000 hospital-days, all patientsc
Mean total 307 219 29 .01
Intravenous therapy 115 69 40 .01
Oral therapy 192 150 22 .13
Per 1000 treatment-daysd
Mean total 546 525 4 .30
Intravenous therapy 205 165 20 .41
Oral therapy 342 360 +5 .52
a Data are for 500 patients.
b Before intervention, 232 patients; after intervention, 148 patients.
c Before intervention, 6914 days; after intervention, 6203 days.
d Before intervention, 3891 days; after intervention, 2589 days.
biotic drug costs. Average DDDs and costs were calculated: (1)
per patient admitted, (2) per patient treated, (3) per 1000 hos-
pital-days, and (4) per 1000 treatment-days. DDDs and costs
were also calculated separately for intravenously and orally de-
livered antibiotics. Costs for nurses’ workload, for intravenous
solutions, and for the infusion equipment were added to the
total drug costs.
The x2 test was used for comparison of categorical variables.
Student’s t test was performed for continuous variables. For all
analyses, we used 2-sided tests. Analysis was performed by SAS
software, version 8.2 (SAS Institute).
RESULTS
Patient characteristics. The 2 groups were comparable with
respect to age, sex distribution, and principal diagnosis (table
1). The length of hospital stay was shorter in the intervention
group, but no difference could be observed among those pa-
tients who received antibiotic treatment. The mean highest C-
reactive protein level and the proportion of patients with C-
reactive protein levels of 1250 mg/L and 1300 mg/L before the
intervention were lower than after the intervention, pointing
to more severe infections in patients in the intervention period.
Antibiotic use and cost. Fewer antibiotic treatment courses
were administered after the implementation of the program:
232 (46%) of 500 patients were treated with 1 dose of an-
tibiotic before the program, compared with 148 (30%) after
the intervention ( ). There was generally a propor-P ! .0001
tionate decrease in the number of conditions requiring anti-
biotic treatment (table 1). For example, a separate analysis of
patients with upper respiratory tract infections revealed that,
after the intervention, antibiotics were withheld significantly
more often than before the intervention (47% vs. 24%; Pp
)..04
There was a marked decrease of overall antibiotic consump-
tion after the intervention (table 2), which translated into a
56% reduction of costs for antibiotic drugs. Intravenous drugs
accounted for 190% of cost savings (table 3). Total DDDs per
patient treated with antimicrobial drugs and per 1000 treatment
days did not change; nevertheless, costs were reduced by ap-
proximately one-third as a result of a reduction in the use of
intravenous drugs.
We observed a strong decrease in the delivery of the broad-
spectrum antibiotics ciprofloxacin, ceftriaxone, imipenem-
cilastatin, piperacillin-tazobactam, and ceftazidime, which were
used by 54 patients (23% of treatments) and 15 patients (10%;
) before and after the implementation of the program,Pp .001
respectively. Total DDDs for these drugs decreased from 365
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Table 3. Costs for antibiotics delivered.
Variable
Cost, US$
Difference,
%
Before
intervention
After
intervention
All patients
Total 67,883 29,814 56
Intravenous therapy 58,782 23,264 60
Oral therapy 9101 6551 28
Per patient admitteda
Mean total 135.8 59.6 56
Intravenous therapy 117.3 46.5 60
Oral therapy 18.2 13.1 28
Per patient treatedb
Mean total 292.6 201.5 31
Intravenous therapy 253.4 157.2 38
Oral therapy 39.2 44.3 +13
Per 1000 hospital-days, all patientsc
Mean total 9818 4806 51
Intravenous therapy 8502 3751 56
Oral therapy 1316 1057 20
Per 1000 treatment-daysd
Mean total 17,446 11,515 34
Intravenous therapy 15,108 8986 48
Oral therapy 2339 2530 +9
a Data are for 500 patients.
b Before intervention, 232 patients; after intervention, 148 patients.
c Before intervention, 6914 days, after intervention, 6203 days.
d Before intervention, 3891 days; after intervention, 2589 days.
Table 4. Drug-associated plus non–drug-associated costs of antimicrobial
treatment.
Variable
Cost, US$
Difference,
US$ (%)
Before
intervention
After
intervention
All patients 93,605 43,595 50,010 (53)
Per patienta 187.3 87.1 100.2 (53)
Per patient treated 403.5 294.6 108.9 (27)
Per 1000 hospital-days, all patients 13,538 7028 6510 (48)
Per 1000 treatment-days 24,057 16,838 7219 (30)
a Data are for 500 patients.
to 104, which saved US$27,340, or 72% of the total drug cost
reduction. Decreases were also noted for other antibiotics
(amoxicillin, clarithromycin, metronidazole, cefuroxime, flu-
cloxacillin, aminoglycosides, rifampin, and vancomycin),
whereas the use of amoxicillin-clavulanate, penicillin, doxy-
cycline, and trimethoprim-sulfamethoxazole increased. No
other antibiotics were used.
Inclusion of nonantibiotic drug costs (i.e., workload, infu-
sion equipment, and drip solutions) for intravenous treatment
(US$32.27 per intravenous DDD) translated into additional
total costs of US$25,722 for the preintervention and US$13,780
for the postintervention group. Total expenditures for anti-
microbial therapy decreased by 150% with inclusion of these
costs (table 4).
Characteristics of antimicrobial treatment. In general, al-
though the difference was not statistically significant, antibiotics
were administered more frequently orally (45% vs. 49%) and
less frequently by intravenous delivery alone (29% vs. 24%).
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Table 5. Outcome assessment of study groups.
Outcome parameter
Before
intervention
After
intervention P
Mortality
Overall 49/500 (9.8) 42/500 (8.4) .44
Patients treated with antibiotics 38/232 (16.4) 28/148 (18.9) .52
Patients treated with antibiotics who died of infection 18/38 (47) 12/28 (43) .72
Patients without antibiotics 11/268 (4.1) 14/352 (4.0) .94
Patients without antibiotics who died of infection 2/11 (18) 0/14 (0) .18
Total infection-related mortality 20/500 (4.0) 12/500 (2.4) .15
Cure or improvement 194/232 (84) 120/148 (81) .52
Relapse during hospital stay 4/232 (1.7) 2/148 (1.4) .72
Length of stay, median, days
All patients 11 9
Antibiotic-treated patients 13 12
Percentage of patients discharged from the hospital
while receiving antibiotics 40.6 39.5 .84
Rehospitalization rate
Total 40/500 (8.0) 43/500 (8.6) .60
Due to infection (relapse included) 9/500 (1.8) 5/500 (1.0) .28
Relapse 4/232 (1.7) 1/148 (0.7) .65
NOTE. Data are n/N (%), unless otherwise indicated.
Switches from intravenous to oral antibiotic use were per-
formed equally often (26% vs. 27%) and occurred in both
groups after a median of 3.0 days. The mean number of an-
tibiotics per patient (1.4) was identical in both groups, and in-
hospital treatment duration was 1 day shorter after the inter-
vention (median, 8.0 vs. 7.0 days). The percentage of patients
who completed the antibiotic treatment regimen after discharge
from the hospital was identical (40.6% and 39.5%).
Outcome of antimicrobial treatment. Overall mortality
did not change after the intervention, whereas the infectious
disease–specific mortality rate decreased from 4.0% to 2.4%
(table 5). The percentages of patients with clinical improvement
and cure were similar in both observation periods. Relapses
during the hospital stay or after discharge and necessitating
readmittance were slightly less frequent after the intervention.
The overall rehospitalization rate was the same in both groups.
In patients who needed rehospitalization, there was no hint of
infections that had been missed during the previous hospital
stay.
Costs of development, implementation, and maintenance of
the program. No new positions were created for setting up
and maintaining the program, nor were any other activities
curtailed. The development of the guidelines in 1997 required,
in total, ∼200 h. The implementation of the program through
lectures and weekly rounds in 1997 required ∼350 h for the
whole medical staff. The maintenance of the project (i.e., lec-
tures, rounds, and revision of guidelines), required ∼500–600
h per year for the whole medical staff. The theoretical costs for
these hours can be calculated to ∼US$20,000 for develop-
ment and implementation and to ∼US$20,000 per year for
maintenance.
Long-term effect of the program. Compared with 1996
(the last full year before the intervention), average total DDDs
per patient admitted to the Department of Internal Medicine
were down 35% in 1998 (the first full year with intervention),
and they were down 26% in 2001 (figure 1). Average intra-
venous DDDs were down 55% and 48%, and average oral
DDDs 23% and 13% in the corresponding time period. Average
antibiotic drug costs per patient admitted to the medical wards
and to the ICU decreased by 51% and 50%, respectively, be-
tween 1996 and 1998 (figure 2). Costs remained fairly stable
during the next few years (decreases in 2001 of 46% and 39%,
respectively, compared with 1996).
Susceptibility patterns of bacterial organisms showed a
slightly favorable trend toward some broad-spectrum antibi-
otics (table 6), but the small numbers do not permit any de-
finitive conclusions to be drawn.
DISCUSSION
This study demonstrates that an easily applicable and inexpen-
sive multifaceted intervention program was highly effective in
reducing the number and costs of antibiotics prescribed. Av-
erage cost savings per patient admitted amounted to US$100,
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Figure 1. Bar graph illustrating antibiotic consumption in defined daily
doses (DDD) per patient admitted to the medical department (not including
intensive care unit admissions) 1996–2001. The last year before inter-
vention measures was 1996, and 1998 was the first year that the in-
tervention program was fully introduced.
Figure 2. Bar graph illustrating antibiotic drug costs per patient admitted to the medical department (black bars, costs for intravenous antibiotics;
white bars, costs for oral antibiotics) and to the intensive care unit (hatched bars, costs for intravenous plus oral antibiotics) for 1996–2001. The last
year before intervention measures was 1996, and 1998 was the first year that the intervention program was fully introduced.
resulting in projected annual savings for our medical depart-
ment in the amount of US$200,000. The program did not
unfavorably affect overall mortality, infection-related mortality,
or relapse rates for serious infections. We could demonstrate a
persistence of the program’s effectiveness over a 4-year obser-
vation period. The 2 most important factors leading to cost
savings were a reduction in the use of unnecessary antibiotic
treatments and a more diligent use of expensive intravenous
broad-spectrum antibiotics.
Our study has several limitations. First, this was not a ran-
domized trial, which would have been difficult to perform
within a single department because of knowledge contamina-
tion between groups. However, physicians were unaware that
this study was performed, which allowed us to test the effect
of the program on the treatment behavior of the same physi-
cians in a real-world setting. Second, we did not evaluate the
individual physicians’ compliance with the implemented guide-
lines with a formal peer-review process. Third, we cannot ex-
clude with certainty that the decrease in the number of anti-
biotic treatment courses was the result of an underlying
decrease in the number of infections and in the patients’ need
for antibiotic treatment. Our analyses of indicators for disease
severity revealed no decrease of severe infections during the
intervention period. However, there was a substantial reduction
in the number of antibiotic prescriptions for certain conditions,
such as upper respiratory tract infections. We interpret this
change not as a shift of the infectious disease pattern but as
the result of a more critical use of antibiotics and as one con-
sequence of our intervention program. The long-term devel-
opment of antibiotic expenditures, with a steady increase from
1992 until 1996 (data not shown), and the sharp and sustained
decrease after the intervention additionally point to a more
critical use of antibiotics as the likely reason for the decrease
of treatments. Fourth, postdischarge follow-up was restricted
to the evaluation of the need for rehospitalization. Thus, we
cannot exclude the notion that, after the intervention, the out-
come of antibiotic treatment was different for patients who
were not in need of rehospitalization. Fifth, we limited the long-
term follow-up to antibiotic consumption and costs without
further controlling for treatment outcomes by chart review.
The study has several strengths: the short-term analysis of
the intervention program is based on individual patient data
extracted in great detail directly from the medical charts. This
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Table 6. Resistance patterns of selected bacterial organisms toward 6 antibiotics during 1996–2001.
Organism
Percentage of resistant or intermediately resistant organisms, by drug
Ciprofloxacin
Imipenem-
cilastatin Ceftazidime
Piperacillin-
tazobactam
Amoxicillin-
clavulanate Cefuroxime
Escherichia coli
1996 1 0 0 2 26 3
1997 1 0 0 2 26 2
1998 3 1 0 2 23 3
1999 1 0 0 1 27 2
2000 2 0 0 NT 18 2
2001 3 0 0 NT 22 1
Klebsiella pneumoniae
1996 11 0 0 15 16 11
1997 0 0 0 17 7 7
1998 7 0 0 0 0 0
1999 0 0 0 0 7 3
2000 0 0 0 NT 13 0
2001 0 0 0 NT 18 0
Pseudomonas aeruginosa
1996 15 15 9 6 NT NT
1997 10 27 5 0 NT NT
1998 27 15 4 0 NT NT
1999 13 4 0 0 NT NT
2000 9 13 17 NT NT NT
2001 5 16 0 NT NT NT
Staphylococcus aureus
1996 NT NT NT NT 0 0
1997 NT NT NT NT 0 0
1998 NT NT NT NT 0 2
1999 NT NT NT NT 0 0
2000 NT NT NT NT 7 7
2001 NT NT NT NT 0 0
Enterococcus species
1996 NT NT NT NT 0 NT
1997 NT NT NT NT 0 NT
1998 NT NT NT NT 0 NT
1999 NT NT NT NT 0 NT
2000 NT NT NT NT 2 NT
2001 NT NT NT NT 6 NT
NOTE. The year that the intervention program was fully introduced was 1998. NT, not tested.
allowed us to make very precise cost calculations, and to analyze
in detail the behavior changes of the physicians and the main
reasons for the cost reduction observed after the multifaceted
intervention. Second, all patients admitted were included, and
the follow-up regarding the need for a rehospitalization was
complete for all patients. Third, the follow-up period was long;
most studies document follow-up periods of !1 year [12, 13,
19, 22] or of 1–2 years [3, 10, 11, 18, 20, 21]. Only 1 study,
which evaluated a computer-assisted decision-support pro-
gram, documented a favorable long-term effect over 7 years
[15].
Apart from avoiding unnecessary antibiotic treatments and
a more diligent use of expensive broad-spectrum antibiotics, a
priori oral delivery, and early switching from the intravenous
to the oral route of administration are recognized as important
cost-lowering strategies in the literature [9]. In our study, we
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observed only a marginal difference associated with these fac-
tors, which was probably because good performance was al-
ready in place before the intervention.
DDDs and calculated costs per admitted and treated patient
or per hospital and treatment day were rather low, compared
with other studies [10, 11, 13, 15, 17, 18, 20, 22, 24]. However,
comparison with these studies is limited as a result of differ-
ences in settings, inclusion in these studies of nonmedical pa-
tients, and different case mix. The same holds true for direct
comparisons of costs, which are further flawed by price dif-
ferences and general differences of health cost structures be-
tween countries.
The acute and sustained cost reduction achieved by our in-
tervention program is substantial. Remarkably, it was attained
in a setting with a rapidly changing medical staff that consists,
in large part, of physician-trainees. In addition, it was achieved
not by computer assistance, but by combining several methods
under the responsibility of one person—probably the most
important factor for the long-lasting success. Such a strategy
may be more feasible in smaller community hospitals and single
departments where sophisticated computer aids may not be
readily available. The generalizability of our findings to larger
medical departments with a different case mix—for example,
university hospitals—may be limited, however. In such settings,
or in countries with higher expenditures for hospital staff, costs
for such an intervention program could be greater and con-
sequently savings smaller than in the present study. Similarly,
unlike at our hospital, in other settings or countries, including
United States hospitals, the implementation and maintenance
of such an antibiotic-management program may not be feasible
without additional monetary support of the staff by hospital
administration.
In summary, in a medical department at a community hos-
pital, an inexpensive comprehensive intervention program
aimed at reducing expenditures for antibiotic treatment proved
to be highly successful in the short and long term and can be
a reasonable means for cost containment in similar settings.
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